Market Spotlight: Hodgkin’s Lymphoma
Market Spotlight: Hodgkin’s Lymphoma
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2016, there were 70,700 incident cases of Hodgkin’s lymphoma worldwide, and expects that number to increase to 77,400 incident cases by 2025.
- Incidence rates are slightly higher in males compared to females. The approved drugs in the Hodgkin’s lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, deoxyribonucleic acid, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of approved drugs are administered via the intravenous route.
- The majority of industry-sponsored drugs in active clinical development for Hodgkin’s lymphoma are in Phase II, with no drugs in Phase III.
- Therapies in the pipeline for Hodgkin’s lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the oral and intravenous routes, with only one product being tested in an intratumoral formulation.
- High-impact upcoming events for drugs in the Hodgkin’s lymphoma space comprise topline Phase IIa trial results for AFM13, and a supplemental CHMP opinion for Adcetris.
- The overall likelihood of approval of a Phase I hematologic asset is 10.9%, and the average probability a drug advances from Phase III is 57.6%. Drugs, on average, take 8.7 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 41 licensing and asset acquisition deals involving Hodgkin’s lymphoma drugs during 2013–18. The largest deal was the $1,410m exclusive licensing agreement in August 2017 between Dermira and Roche/Genentech for the development and commercialization of lebrikizumab.
- The clinical trials distribution across Phase I–IV indicates that the vast majority of trials for Hodgkin’s lymphoma have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
- The US has a substantial lead in the number of Hodgkin’s lymphoma clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the Hodgkin’s lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin’s lymphoma, with 46 trials.
- Takeda leads industry sponsors with by far the highest number of clinical trials for Hodgkin’s lymphoma, followed by Merck & Co.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
10 Radiation therapy
11 Stem cell transplantation (SCT)
17 MARKETED DRUGS
20 Approvals by country
23 PIPELINE DRUGS
30 RECENT EVENTS AND ANALYST OPINION
30 Adcetris for Hodgkin’s Lymphoma (June 26, 2017)
32 KEY UPCOMING EVENTS
33 KEY REGULATORY EVENTS
33 China Roundup: Innovent I/O Setback, Adagene, Hua Bag Millions, WuXi Relisting
33 Seattle Genetics Says Adcetris Sets New Standard In Frontline Lymphoma
33 Seattle Genetics Looking To Improve, Replace Standards Of Care
33 Blood Cancer Sector More Competitive After Keytruda Approval
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
36 PARENT PATENTS
37 REVENUE OPPORTUNITY
38 CLINICAL TRIAL LANDSCAPE
39 Trials by status
40 Trials by phase
42 Prescription information
LIST OF FIGURES
14 Figure 1: Trends in incident cases of Hodgkin’s lymphoma, 2017–26
23 Figure 2: Overview of pipeline drugs for Hodgkin’s lymphoma in the US
24 Figure 3: Pipeline drugs for Hodgkin’s lymphoma, by company
24 Figure 4: Pipeline drugs for Hodgkin’s lymphoma, by drug type
24 Figure 5: Pipeline drugs for Hodgkin’s lymphoma, by classification
31 Figure 6: Adcetris for Hodgkin’s Lymphoma (June 26, 2017): Phase III – ECHELON-1
32 Figure 7: Key upcoming events in Hodgkin’s lymphoma
34 Figure 8: Probability of success in the Hodgkin’s lymphoma pipeline
35 Figure 9: Licensing and asset acquisition deals in Hodgkin’s lymphoma, 2013–18
36 Figure 10: Parent patents in Hodgkin’s lymphoma
38 Figure 11: Clinical trials in Hodgkin’s lymphoma
38 Figure 12: Top 10 drugs for clinical trials in Hodgkin’s lymphoma
39 Figure 13: Top 10 companies for clinical trials in Hodgkin’s lymphoma
39 Figure 14: Trial locations in Hodgkin’s lymphoma
40 Figure 15: Hodgkin’s lymphoma trials status
41 Figure 16: Hodgkin’s lymphoma trials sponsors, by phase
LIST OF TABLES
13 Table 1: Incident cases of Hodgkin’s lymphoma, 2017–26
15 Table 2: Five-Year prevalent cases of Hodgkin’s Lymphoma, 2017–26
18 Table 3: Marketed drugs for Hodgkin’s lymphoma
21 Table 4: Approvals by country for Hodgkin’s lymphoma
26 Table 5: Pipeline drugs for Hodgkin’s lymphoma in the US
30 Table 6: Adcetris for Hodgkin’s Lymphoma (June 26, 2017)
37 Table 7: Historical global sales, by drug ($m), 2013–17
37 Table 8: Forecasted global sales, by drug ($m), 2018–22
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.